The Effect of Open-Label Semaglutide on Metabolic Dysfunction-Associated Steatotic Liver Disease in People With HIV
Ann Intern Med
.
2024 Apr 30.
doi: 10.7326/M23-3354.
Online ahead of print.
Authors
Jordan E Lake
1
,
Douglas W Kitch
2
,
Amy Kantor
2
,
Raja Muthupillai
3
,
Karin L Klingman
4
,
Christina Vernon
5
,
Pablo F Belaunzaran-Zamudio
6
,
Carl J Fichtenbaum
7
,
Sonya Heath
8
,
Hugo Perazzo
9
,
Kathleen Corey
10
,
Todd T Brown
11
,
Alan Landay
12
,
Fred Sattler
13
,
Kristine M Erlandson
14
Affiliations
1
UTHealth Houston, Houston, Texas.
2
Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
3
School of Engineering Medicine, Texas A&M University, Houston, Texas, and ForeSpect PLLC, Pearland, Texas.
4
Weill Cornell College of Medicine, New York, New York.
5
Social & Scientific Systems, Inc., and FHI 360, Durham, North Carolina.
6
National Institute of Allergy and Infectious Diseases, Rockville, Maryland.
7
University of Cincinnati, Cincinnati, Ohio.
8
University of Alabama at Birmingham, Birmingham, Alabama.
9
Evandro Chagas National Institute of Infectious Diseases, Rio de Janeiro, Rio de Janeiro, Brazil.
10
Massachusetts General Hospital, Boston, Massachusetts.
11
Johns Hopkins University, Baltimore, Maryland.
12
Rush University, Chicago, Illinois.
13
University of Southern California, Los Angeles, California.
14
University of Colorado Anschutz Medical Campus, Aurora, Colorado.
PMID:
38684100
DOI:
10.7326/M23-3354
No abstract available
Grants and funding
U01 AI068634/AI/NIAID NIH HHS/United States
U01 AI068636/AI/NIAID NIH HHS/United States